Fondaparinux Market Analysis by Product (Branded/Generic), and Segment Forecasts to 2024
The global fondaparinux market is expected to reach USD 686.3 million by 2024, according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.
Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events
The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy’s Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.
Further key Findings From the Study Suggest:
Generics and authorized generics of Arixtra (fondaparinux sodium) dominated the market in 2015 with share of over 65.0%
The introduction of generic drugs in the market by Apotex, Inc., Dr. Reddy’s, and Mylan N.V. is expected to drive the market growth.
Branded drug Arixtra is however anticipated to witness declining growth rate majorly owing to patent expiration, high cost, and introduction of low-cost alternatives
North America held the largest market share of the global market in 2015. Key factors attributing to the dominance include constantly increasing geriatric population, rising prevalence of thrombosis, and the introduction of low-cost generics of Fondaparinux in the U.S.
In addition, the increasing number of awareness initiatives undertaken by government and nongovernment organizations for DVT and PE is driving the growth of the market in the North American region.
China’s huge population base with the rising disposable income coupled with the increased burden of chronic diseases is expected to be one of the major drivers for the Chinese market over the forecast period.
Moreover, the presence of local active pharmaceutical ingredients manufacturers and contract research organizations in China increased the number of foreign investments in the country. As a result, China is estimated to grow at CAGR of 21.2% till 2024
Major companies identified in the market include Dr. Reddy’s Laboratories, Inc., GSK group of companies, Mylan N.V., and Alchemia among others.
The Fondaparinux market is a consolidated market and is marked by the presence of mergers and acquisitions
Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events
The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy’s Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.
Further key Findings From the Study Suggest:
Generics and authorized generics of Arixtra (fondaparinux sodium) dominated the market in 2015 with share of over 65.0%
The introduction of generic drugs in the market by Apotex, Inc., Dr. Reddy’s, and Mylan N.V. is expected to drive the market growth.
Branded drug Arixtra is however anticipated to witness declining growth rate majorly owing to patent expiration, high cost, and introduction of low-cost alternatives
North America held the largest market share of the global market in 2015. Key factors attributing to the dominance include constantly increasing geriatric population, rising prevalence of thrombosis, and the introduction of low-cost generics of Fondaparinux in the U.S.
In addition, the increasing number of awareness initiatives undertaken by government and nongovernment organizations for DVT and PE is driving the growth of the market in the North American region.
China’s huge population base with the rising disposable income coupled with the increased burden of chronic diseases is expected to be one of the major drivers for the Chinese market over the forecast period.
Moreover, the presence of local active pharmaceutical ingredients manufacturers and contract research organizations in China increased the number of foreign investments in the country. As a result, China is estimated to grow at CAGR of 21.2% till 2024
Major companies identified in the market include Dr. Reddy’s Laboratories, Inc., GSK group of companies, Mylan N.V., and Alchemia among others.
The Fondaparinux market is a consolidated market and is marked by the presence of mergers and acquisitions
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Research Methodology
1.2 Geographic Scope & Assumptions
1.3 Years Considered
1.4 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 INTRODUCTION
3.1 Key Findings
3.2 Value Chain Analysis
3.2.1 Upstream
3.2.2 Downstream
CHAPTER 4 MANUFACTURE
4.1 Manufacturing Process
4.2 Issues and Trends
CHAPTER 5 COST STRUCTURE
5.1 Bill of Material
5.2 Manufacturing Cost
5.3 Labor Cost
5.4 Depreciation Cost
CHAPTER 6 WORLDWIDE KEY VENDORS
6.1 Profile
6.1.1 GlaxoSmithKline (GSK) Plc
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Alchemia Ltd.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Apotex, Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 Dr Reddy's Laboratories Ltd.
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Product Benchmarking
6.1.4.4 Strategic Initiatives
6.1.5 ScinoPharm Taiwan., Ltd.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Product Benchmarking
6.1.5.4 Strategic Initiatives
6.1.6 Lupin Pharmaceuticals, Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Product Benchmarking
6.1.6.4 Strategic Initiatives
6.1.7 Abbott Laboratories, Inc.
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Product Benchmarking
6.1.7.4 Strategic Initiatives
6.2 Market Share Trends
CHAPTER 7 MARKET STATUS
7.1 Market Size, 2015
7.1.1 Global Fondaparinux market, 2011 - 2024 (USD million)
7.2 Market Volume, 2015
7.2.1 Global Fondaparinux market, volume, 2011 - 2024 (Thousand Units)
7.3 Competitive Landscape
7.3.1 Heat Map
CHAPTER 8 MARKET OVERVIEW (VARIABLES, TRENDS& SCOPE)
8.1 Market Segmentation & Scope
8.2 Global Production Volume 2011 - 2016
8.2.1 Global Fondaparinux market, volume, 2011 - 2016 (thousand units)
8.3 Production Volume by Region, 2011-2016
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 China
8.3.5 RoW
8.4 Global Production Value, 2011 - 2016
8.4.1 Global Fondaparinux market, 2011 - 2016 (USD million)
8.5 Production Value by Region, 2011 - 2016
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 China
8.5.5 RoW
CHAPTER 9 MARKET FORECAST
9.1 Regional Market Size Forecast, 2016 to 2024
9.1.1 North America
9.1.2 Europe
9.1.3 Asia Pacific
9.1.4 China
9.1.5 RoW
9.2 Regional Consumption Forecast, 2016- 2024
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 China
9.2.5 RoW
CHAPTER 10 MARKET DYNAMICS
10.1 Market Drivers
10.1.1 Expanding applications of Fondaparinux in various therapeutic areas
10.1.2 Expanding target audience in the Fondaparinux market
10.1.3 Introduction of generics in the market
10.2 Market Constraints
10.2.1 High setup cost
10.3 Market Opportunities
CHAPTER 11 INVESTMENT FEASIBILITY
11.1 Global Economic Highlight 2015
11.2 Recent Developments
11.3 The Updated Forecast
11.3.1 Advanced Economies
11.3.2 Emerging Markets and Developing Economies
11.4 China Outlook
11.5 Investment in China
11.5.1 Outlook on investment
11.5.2 Growth opportunities
11.5.3 Policy trends
11.5.4 Conclusions
11.6 Feasibility of New Project
11.6.1 Basis and presumptions
11.6.2 New project
1.1 Research Methodology
1.2 Geographic Scope & Assumptions
1.3 Years Considered
1.4 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 INTRODUCTION
3.1 Key Findings
3.2 Value Chain Analysis
3.2.1 Upstream
3.2.2 Downstream
CHAPTER 4 MANUFACTURE
4.1 Manufacturing Process
4.2 Issues and Trends
CHAPTER 5 COST STRUCTURE
5.1 Bill of Material
5.2 Manufacturing Cost
5.3 Labor Cost
5.4 Depreciation Cost
CHAPTER 6 WORLDWIDE KEY VENDORS
6.1 Profile
6.1.1 GlaxoSmithKline (GSK) Plc
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Alchemia Ltd.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Apotex, Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 Dr Reddy's Laboratories Ltd.
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Product Benchmarking
6.1.4.4 Strategic Initiatives
6.1.5 ScinoPharm Taiwan., Ltd.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Product Benchmarking
6.1.5.4 Strategic Initiatives
6.1.6 Lupin Pharmaceuticals, Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Product Benchmarking
6.1.6.4 Strategic Initiatives
6.1.7 Abbott Laboratories, Inc.
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Product Benchmarking
6.1.7.4 Strategic Initiatives
6.2 Market Share Trends
CHAPTER 7 MARKET STATUS
7.1 Market Size, 2015
7.1.1 Global Fondaparinux market, 2011 - 2024 (USD million)
7.2 Market Volume, 2015
7.2.1 Global Fondaparinux market, volume, 2011 - 2024 (Thousand Units)
7.3 Competitive Landscape
7.3.1 Heat Map
CHAPTER 8 MARKET OVERVIEW (VARIABLES, TRENDS& SCOPE)
8.1 Market Segmentation & Scope
8.2 Global Production Volume 2011 - 2016
8.2.1 Global Fondaparinux market, volume, 2011 - 2016 (thousand units)
8.3 Production Volume by Region, 2011-2016
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 China
8.3.5 RoW
8.4 Global Production Value, 2011 - 2016
8.4.1 Global Fondaparinux market, 2011 - 2016 (USD million)
8.5 Production Value by Region, 2011 - 2016
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 China
8.5.5 RoW
CHAPTER 9 MARKET FORECAST
9.1 Regional Market Size Forecast, 2016 to 2024
9.1.1 North America
9.1.2 Europe
9.1.3 Asia Pacific
9.1.4 China
9.1.5 RoW
9.2 Regional Consumption Forecast, 2016- 2024
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 China
9.2.5 RoW
CHAPTER 10 MARKET DYNAMICS
10.1 Market Drivers
10.1.1 Expanding applications of Fondaparinux in various therapeutic areas
10.1.2 Expanding target audience in the Fondaparinux market
10.1.3 Introduction of generics in the market
10.2 Market Constraints
10.2.1 High setup cost
10.3 Market Opportunities
CHAPTER 11 INVESTMENT FEASIBILITY
11.1 Global Economic Highlight 2015
11.2 Recent Developments
11.3 The Updated Forecast
11.3.1 Advanced Economies
11.3.2 Emerging Markets and Developing Economies
11.4 China Outlook
11.5 Investment in China
11.5.1 Outlook on investment
11.5.2 Growth opportunities
11.5.3 Policy trends
11.5.4 Conclusions
11.6 Feasibility of New Project
11.6.1 Basis and presumptions
11.6.2 New project
LIST OF TABLES
Table 1 Death rates and severe bleeding: Fondaparinux versus low molecular weight heparin
Table 1 Death rates and severe bleeding: Fondaparinux versus low molecular weight heparin
